Expression of IFN-β enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma

Candice L. Willmon, Vassiliki Saloura, Zvi G. Fridlender, Phonphimon Wongthida, Rosa Maria Diaz, Jill Thompson, Timothy Kottke, Mark Federspiel, Glen N Barber, Steven M. Albelda, Richard G. Vile

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Our preclinical and clinical trials using a replication-defective adenoviral vector expressing IFN-β have shown promising results for the treatment of malignant mesothelioma. Based on the hypotheses that a replication-competent vesicular stomatitis virus (VSV) oncolytic vector would transduce more tumor cells in vivo, that coexpression of the immunostimulatory IFN-β gene would enhance the immune-based effector mechanisms associated both with regression of mesotheliomas and with VSV-mediated virotherapy, and that virus-derived IFN-β would add further safety to the VSV platform, we tested the use of IFN-β as a therapeutic transgene expressed from VSV as a novel treatment for mesothelioma. VSV-IFN-β showed significant therapy against AB12 murine mesotheliomas in the context of both local and locoregional viral delivery. Biologically active IFN-β expressed from VSV added significantly to therapy compared with VSV alone, dependent in part on host CD8+ T-cell responses. Immune monitoring suggested that these antitumor T-cell responses may be due to a generalized T-cell activation rather than the priming of tumor antigen-specific T-cell responses. Finally, IFN-β also added considerable extra safety to the virus by providing protection from off-target viral replication in nontumor tissues and protected severe combined immunodeficient mice from developing lethal neurotoxicity. The enhanced therapeutic index provided by the addition of IFN-β to VSV therefore provides a powerful justification for the development of this virus for future clinical trials.

Original languageEnglish
Pages (from-to)7713-7720
Number of pages8
JournalCancer Research
Volume69
Issue number19
DOIs
StatePublished - Oct 1 2009

Fingerprint

Vesicular Stomatitis
Mesothelioma
Viruses
Safety
T-Lymphocytes
Therapeutics
Clinical Trials
Oncolytic Viruses
Immunologic Monitoring
SCID Mice
Neoplasm Antigens
Transgenes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Willmon, C. L., Saloura, V., Fridlender, Z. G., Wongthida, P., Diaz, R. M., Thompson, J., ... Vile, R. G. (2009). Expression of IFN-β enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Research, 69(19), 7713-7720. https://doi.org/10.1158/0008-5472.CAN-09-1013

Expression of IFN-β enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. / Willmon, Candice L.; Saloura, Vassiliki; Fridlender, Zvi G.; Wongthida, Phonphimon; Diaz, Rosa Maria; Thompson, Jill; Kottke, Timothy; Federspiel, Mark; Barber, Glen N; Albelda, Steven M.; Vile, Richard G.

In: Cancer Research, Vol. 69, No. 19, 01.10.2009, p. 7713-7720.

Research output: Contribution to journalArticle

Willmon, CL, Saloura, V, Fridlender, ZG, Wongthida, P, Diaz, RM, Thompson, J, Kottke, T, Federspiel, M, Barber, GN, Albelda, SM & Vile, RG 2009, 'Expression of IFN-β enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma', Cancer Research, vol. 69, no. 19, pp. 7713-7720. https://doi.org/10.1158/0008-5472.CAN-09-1013
Willmon, Candice L. ; Saloura, Vassiliki ; Fridlender, Zvi G. ; Wongthida, Phonphimon ; Diaz, Rosa Maria ; Thompson, Jill ; Kottke, Timothy ; Federspiel, Mark ; Barber, Glen N ; Albelda, Steven M. ; Vile, Richard G. / Expression of IFN-β enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. In: Cancer Research. 2009 ; Vol. 69, No. 19. pp. 7713-7720.
@article{66a6cf615cc54d999d6e2fd2902b9676,
title = "Expression of IFN-β enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma",
abstract = "Our preclinical and clinical trials using a replication-defective adenoviral vector expressing IFN-β have shown promising results for the treatment of malignant mesothelioma. Based on the hypotheses that a replication-competent vesicular stomatitis virus (VSV) oncolytic vector would transduce more tumor cells in vivo, that coexpression of the immunostimulatory IFN-β gene would enhance the immune-based effector mechanisms associated both with regression of mesotheliomas and with VSV-mediated virotherapy, and that virus-derived IFN-β would add further safety to the VSV platform, we tested the use of IFN-β as a therapeutic transgene expressed from VSV as a novel treatment for mesothelioma. VSV-IFN-β showed significant therapy against AB12 murine mesotheliomas in the context of both local and locoregional viral delivery. Biologically active IFN-β expressed from VSV added significantly to therapy compared with VSV alone, dependent in part on host CD8+ T-cell responses. Immune monitoring suggested that these antitumor T-cell responses may be due to a generalized T-cell activation rather than the priming of tumor antigen-specific T-cell responses. Finally, IFN-β also added considerable extra safety to the virus by providing protection from off-target viral replication in nontumor tissues and protected severe combined immunodeficient mice from developing lethal neurotoxicity. The enhanced therapeutic index provided by the addition of IFN-β to VSV therefore provides a powerful justification for the development of this virus for future clinical trials.",
author = "Willmon, {Candice L.} and Vassiliki Saloura and Fridlender, {Zvi G.} and Phonphimon Wongthida and Diaz, {Rosa Maria} and Jill Thompson and Timothy Kottke and Mark Federspiel and Barber, {Glen N} and Albelda, {Steven M.} and Vile, {Richard G.}",
year = "2009",
month = "10",
day = "1",
doi = "10.1158/0008-5472.CAN-09-1013",
language = "English",
volume = "69",
pages = "7713--7720",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Expression of IFN-β enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma

AU - Willmon, Candice L.

AU - Saloura, Vassiliki

AU - Fridlender, Zvi G.

AU - Wongthida, Phonphimon

AU - Diaz, Rosa Maria

AU - Thompson, Jill

AU - Kottke, Timothy

AU - Federspiel, Mark

AU - Barber, Glen N

AU - Albelda, Steven M.

AU - Vile, Richard G.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Our preclinical and clinical trials using a replication-defective adenoviral vector expressing IFN-β have shown promising results for the treatment of malignant mesothelioma. Based on the hypotheses that a replication-competent vesicular stomatitis virus (VSV) oncolytic vector would transduce more tumor cells in vivo, that coexpression of the immunostimulatory IFN-β gene would enhance the immune-based effector mechanisms associated both with regression of mesotheliomas and with VSV-mediated virotherapy, and that virus-derived IFN-β would add further safety to the VSV platform, we tested the use of IFN-β as a therapeutic transgene expressed from VSV as a novel treatment for mesothelioma. VSV-IFN-β showed significant therapy against AB12 murine mesotheliomas in the context of both local and locoregional viral delivery. Biologically active IFN-β expressed from VSV added significantly to therapy compared with VSV alone, dependent in part on host CD8+ T-cell responses. Immune monitoring suggested that these antitumor T-cell responses may be due to a generalized T-cell activation rather than the priming of tumor antigen-specific T-cell responses. Finally, IFN-β also added considerable extra safety to the virus by providing protection from off-target viral replication in nontumor tissues and protected severe combined immunodeficient mice from developing lethal neurotoxicity. The enhanced therapeutic index provided by the addition of IFN-β to VSV therefore provides a powerful justification for the development of this virus for future clinical trials.

AB - Our preclinical and clinical trials using a replication-defective adenoviral vector expressing IFN-β have shown promising results for the treatment of malignant mesothelioma. Based on the hypotheses that a replication-competent vesicular stomatitis virus (VSV) oncolytic vector would transduce more tumor cells in vivo, that coexpression of the immunostimulatory IFN-β gene would enhance the immune-based effector mechanisms associated both with regression of mesotheliomas and with VSV-mediated virotherapy, and that virus-derived IFN-β would add further safety to the VSV platform, we tested the use of IFN-β as a therapeutic transgene expressed from VSV as a novel treatment for mesothelioma. VSV-IFN-β showed significant therapy against AB12 murine mesotheliomas in the context of both local and locoregional viral delivery. Biologically active IFN-β expressed from VSV added significantly to therapy compared with VSV alone, dependent in part on host CD8+ T-cell responses. Immune monitoring suggested that these antitumor T-cell responses may be due to a generalized T-cell activation rather than the priming of tumor antigen-specific T-cell responses. Finally, IFN-β also added considerable extra safety to the virus by providing protection from off-target viral replication in nontumor tissues and protected severe combined immunodeficient mice from developing lethal neurotoxicity. The enhanced therapeutic index provided by the addition of IFN-β to VSV therefore provides a powerful justification for the development of this virus for future clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=70350230280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350230280&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-1013

DO - 10.1158/0008-5472.CAN-09-1013

M3 - Article

C2 - 19773437

AN - SCOPUS:70350230280

VL - 69

SP - 7713

EP - 7720

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 19

ER -